Elicio Therapeutics Ownership
| ELTX Stock | 5.12 0.11 2.20% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Elicio |
Elicio Stock Ownership Analysis
About 26.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.44. Elicio Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 2nd of June 2023. To learn more about Elicio Therapeutics call Robert Connelly at 857-209-0050 or check out https://elicio.com.Besides selling stocks to institutional investors, Elicio Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Elicio Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Elicio Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Elicio Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 26.0% of Elicio Therapeutics are currently held by insiders. Unlike Elicio Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Elicio Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Elicio Therapeutics' insider trades
Elicio Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Elicio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Elicio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Elicio Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Haqq Christopher over a month ago Acquisition by Haqq Christopher of 28200 shares of Elicio Therapeutics at 5.03 subject to Rule 16b-3 | ||
Chudnovsky Yekaterina over six months ago Acquisition by Chudnovsky Yekaterina of 1032702 shares of Elicio Therapeutics at 0.01 subject to Rule 16b-3 | ||
Omenn Gilbert S over six months ago Conversion by Omenn Gilbert S of 23391 shares of Elicio Therapeutics | ||
Nissenson Allen over six months ago Acquisition by Nissenson Allen of 4100 shares of Elicio Therapeutics subject to Rule 16b-3 | ||
Nissenson Allen over six months ago Purchase by Nissenson Allen of 2037 shares of Elicio Therapeutics | ||
Neylan John F over a year ago Sale by Neylan John F of 442 shares of Elicio Therapeutics | ||
Rhodes Jennifer J over a year ago ELICIO THERAPEUTICS exotic insider transaction detected | ||
Ruffolo Robert R over a year ago ELICIO THERAPEUTICS exotic insider transaction detected | ||
Piekos Brian over a year ago Acquisition by Piekos Brian of 75484 shares of ELICIO THERAPEUTICS subject to Rule 16b-3 |
Elicio Therapeutics Corporate Filings
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 27th of September 2024 Other Reports | ViewVerify | |
| 17th of September 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.